生物制剂在老年类风湿关节炎患者中的安全性
Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis.
作者信息
Murota Atsuko, Kaneko Yuko, Yamaoka Kunihiro, Takeuchi Tsutomu
机构信息
From the Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
A. Murota, MD, PhD, Postdoctoral Fellow, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; Y. Kaneko, MD, PhD, Assistant Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; K. Yamaoka, MD, PhD, Associate Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; T. Takeuchi, MD, PhD, Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine.
出版信息
J Rheumatol. 2016 Nov;43(11):1984-1988. doi: 10.3899/jrheum.160012. Epub 2016 Sep 1.
OBJECTIVE
To clarify the safety of biologics in elderly patients with rheumatoid arthritis.
METHODS
Biologics were analyzed for safety in relation to age in 309 patients.
RESULTS
Young (< 65 yrs old, n = 174), elderly (65-74 yrs old, n = 86), and older elderly patients (≥ 75 yrs old, n = 49) were enrolled. Although the incidence of adverse events causing treatment withdrawal was significantly higher in elderly and old elderly compared with young patients, no difference was found between elderly and older elderly patients. Pulmonary complications were independent risk factors.
CONCLUSION
Old patients require special attention, although the safety of biologics in those ≥ 75 years old and 65-74 was comparable.
目的
阐明生物制剂在老年类风湿关节炎患者中的安全性。
方法
分析了309例患者使用生物制剂的安全性与年龄的关系。
结果
纳入了年轻患者（<65岁，n = 174）、老年患者（65 - 74岁，n = 86）和高龄老年患者（≥75岁，n = 49）。尽管导致治疗中断的不良事件发生率在老年和高龄老年患者中显著高于年轻患者，但老年患者和高龄老年患者之间未发现差异。肺部并发症是独立的危险因素。
结论
老年患者需要特别关注，尽管生物制剂在75岁及以上和65 - 74岁患者中的安全性相当。
Zotero 插件